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Background: Pertussis is mainly considered as a disease of childhood. However, an increasing
number of adults with infection due to Bordetella pertussis is reported in the literature.
Methods: A retrospective cohort study of patients with a new origin-cough of more than 3
weeks duration who were evaluated by an internal medicineeinfectious diseases group prac-
tice in Athens, Greece during the period 10/2005e12/2007 was performed; patients under-
went serological testing for B. pertussis infection.
Results: Five hundred and fifty-four adult patients underwent B. pertussis serological testing
from whom 441 had a single IgM/IgG measurement. The percentage of seropositivity in the
IgM/IgG B. pertussis serological testing was 71.5% in the population studied (397/554 patients;
for patients who had IgM/IgG B. pertussis serological testing in more than one occasions, only
the result of the first IgM/IgG measurement was taken into account for this analysis). For the
subset of patients with a single IgM/IgG measurement, the percentage of seropositivity against
B. pertussis was 70.7% (312/441 patients).
Conclusions: B. pertussis infection should be considered as a significant pathogenic infection in
a significant proportion of adult patients presenting a new origin-cough of more than 3 weeks
duration. In order to reduce the burden of pertussis disease in adults as well as transmission of
pertussis in children, booster vaccination is recommended for adolescents and adults.
ª 2008 Elsevier Ltd. All rights reserved.e of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece. Tel.: þ30 694
(M.E. Falagas).
8 Elsevier Ltd. All rights reserved.
Bordetella pertussis serology in adult patients 1587Introduction Data extractionIn the prevaccine era, the majority of pertussis cases
occurred in children, resulting in significant morbidity and
mortality. Pertussis epidemics followed a cyclic pattern,
with peaks every 2e5 years.1 The 50-year period of efforts
for pertussis control with the use of various pertussis vac-
cines was followed by a resurgence of pertussis in various
populations during the past 20 years.2 Specifically, pertussis
resurgence was characterized by a change in the epidemio-
logic profile with large outbreaks among adolescents and
adults who had both classic pertussis symptoms and pro-
longed illness with cough.3e6
In Greece, the pediatric population is regarded as
adequately immunized with a vaccination programme
against pertussis consisting mainly of four doses given
at the ages of 2, 4, 6, and 18 months, respectively, and
with a fifth dose recommended at the ages of 4e6 years. 7
However, data provided from previous seroepidemiological
studies indicate an increasing incidence of Bordetella
pertussis infection in Greek adolescents and adults.8,9
In order to contribute to the relevant literature of
seroepidemiology of B. pertussis and provide further infor-
mation on pertussis incidence in the adult Greek popula-
tion, we conducted a retrospective cohort study in
patients who sought medical advice due to a new
origin-cough of duration more than 3 weeks from 10/2005
to 12/2007.Methods
Study design and patient population
A retrospective cohort study was conducted on an
outpatient adult patient population with a new origin-
cough of more than 3 weeks duration, who were
evaluated by an internal medicineeinfectious diseases
group practice in Athens, Greece from 10/2005 to 12/
2007. Serological studies were performed at the De-
partment of Microbiology of ‘‘Henry Dunant’’, a 450-bed
tertiary-care hospital in Athens, Greece. The study
population consisted of 554 adults (216 men and 338
women). We analyzed the relevant serological data
regarding antibody response to specific B. pertussis anti-
gens and consequently estimated the incidence of per-
tussis infection in the study population. The ethics
committee of the Alfa Institute of Biomedical Sciences
(AIBS) approved the study’s protocol.
Laboratory testing
Immunoglobulin M (IgM) and immunoglobulin G (IgG) class
antibodies against B. pertussis were detected by an Enzyme
Linked Immunosorbent Assay (ELISA), commercially avail-
able by Daicel Chemical Industries, Ltd., Osaka, Japan.
The antigen used was pertussis toxin (PT). The number of
measurements of IgM/IgG B. pertussis antibodies at differ-
ent times varied between 1 and 6 in the study population.
No further diagnostic testing for B. pertussis infection was
performed.Serological data were retrieved from the computerized
databases of the Microbiology Laboratory of ‘‘Henry
Dunant’’ Hospital. Two physicians (E.K.V. and P.I.R.) in-
dependently performed the evaluation of data and the
classification of the serological status.
Definitions
An IgG titer of 11 ELISA units/ml (EU/ml) or less was
defined as negative (), whereas an IgG titer> 11 EU/ml
was defined as positive (þ). The cutoff point for IgM was
also 11 EU/ml. Patients with a combination of IgM(þ)/
IgG(þ), IgM(þ)/IgG() or IgM()/IgG(þ) were character-
ized as seropositive, whereas patients with the
combination of IgM()/IgG() were characterized as sero-
negative. A high IgG titer in a single measurement was
accepted as an indicative of recent exposure to B. pertussis
leading to pertussis infection based on the relevant litera-
ture.10e15
Results
The results from the serological testing against B. per-
tussis in the studied population are presented in Table
1. Five hundred and fifty-four patients were included in
the study (338 females and 216 males); 441 patients
underwent a single measurement of IgM and IgG anti-
bodies to B. pertussis and 113 patients more than one
measurement, specifically, 79, 19, 6, 6, and 3 patients
were submitted into 2, 3, 4, 5, and 6 different measure-
ments, respectively. The percentage of seropositivity in
the IgM/IgG B. pertussis serological testing was 71.5%
(397/554) in the population studied (for patients who
had IgM/IgG B. pertussis serological testing in more
than one occasions, only the result of the first IgM/IgG
measurement was taken into account for this analysis).
The IgM(þ)/IgG(þ), IgM(þ)/IgG(), IgM()/IgG(þ), and
IgM()/IgG() combinations were found in 57 (45 fe-
males and 12 males) (10.2%), 2 (0.3%), 338 (194 females
and 144 males) (61.0%), and 157 (28.3%) patients,
respectively.
In a subgroup analysis of the 441 patients who had
a single measurement of IgM and IgG antibodies against B.
pertussis toxin, the IgM(þ)/IgG(þ), IgM(þ)/IgG(),
IgM()/IgG(þ), and IgM()/IgG() combinations were
found in 38 (8.6%), 1 (0.23%), 273 (61.9%) and 129
(29.3%), respectively. Thus, in this subset of patients with
a single IgM/IgG measurement the percentage of those
who were seropositive against B. pertussis was 70.7%
(312/441 patients).
From the 113 patients who had more than one measure-
ment of IgM/IgG antibodies against B. pertussis antigens at
different times, 82 had at least 2 IgM/IgG measurements
within a period of 6 months. The status of 55 of these
patients (67.0%) was seropositive in both measurements,
5 (6.0%) changed from seronegative to seropositive, 6
(7.3%) changed from seropositive to seronegative, and
the remaining 16 (19.5%) were seronegative in both
measurements.
Table 1 Results of the serological testing for Bordetella pertussis antigens in the studied population
Serological status Patients with 1
measurement
Patients with >1
measurementa
Total number
of patients
Patients with at least 2
measurements within
a period 6 months
Seropositive 55 (67.0%)b
IgM(þ)/IgG(þ) 38 (8.6%) 19 (16.8%) 57 (10.2%)
IgM(þ)/IgG() 1 (0.23%) 1 (0.88%) 2 (0.3%)
IgM()/IgG(þ) 273 (61.9%) 65 (57.5%) 338 (61.0%)
Change from seropositive to
seronegative within a period
6 months
6 (7.3%)
Seronegative [IgM()/IgG()] 129 (29.3%) 28 (24.7%) 157 (28.3%) 16 (19.5%)c
Change from seronegative to
seropositive within a period
6 months
5 (6.0%)
Total number of patients 441 113 554 82
a For patients who had IgM/IgG B. pertussis serological testing in more than one occasions, only the result of the first IgM/IgG
measurement was taken into account for this analysis.
b Seropositive in both measurements.
c Seronegative in both measurements.
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The main finding of our study is that approximately 70% of
our adult study population, with a new origin-cough of more
than 3 weeks duration, was seropositive for B. pertussis
infection. Our findings are in accordance with data pro-
vided from other studies, which indicate a prevalence of
high antibody titers against B. pertussis antigens in adult
populations,8,9,16e18 thus reflecting an increasing incidence
of pertussis infection in adults during the last decade.
Given that adults are the main reservoir of B. pertussis
who transmit the pathogen to unvaccinated infants and
inadequately vaccinated children, a vaccine booster is war-
ranted in adults.19e22
In Table 2 we present the main characteristics of a num-
ber of studies conducted during the last 15 years, which
aimed to evaluate B. pertussis seroepidemiology. The stud-
ies refer to patient populations from European countries
such as Greece and Germany, from the United States of
America, and also from Turkey, thus depicting the
increased interest in B. pertussis infection, observed world-
wide. Study populations consisted of either healthy sub-
jects or patients with prolonged or acute paroxysmal
cough. Nasopharyngeal culture, polymerase chain reaction
(PCR) and serological testing against specific B. pertussis
antigens were used to detect B. pertussis infection. Fre-
quencies of high antibody titers are highest in adult popula-
tions, when compared to children.8,9,16 In adult populations
with prolonged cough a percentage up to 35% was found
positive, when using serology as diagnostic method for
B. pertussis infection (data shown in Table 2).4,10,26e28,41,49
The increasing incidence of pertussis infection indicates
a problem of pertussis resurgence in our era, despite the
availability of vaccines. In the prevaccine era, pertussis
infection was mainly regarded as an infection of childhood,
causing significant morbidity and mortality in children.23,24
In the present post-vaccine era, even though the overall
incidence of pertussis has been reduced dramatically dueto the establishment of vaccination against B. pertussis,
the cyclic pattern has not changed. Data generated during
the last 20 years indicate that the circulation of B. pertussis
is occurring in adolescents and adults, manifested by pro-
longed illness with cough.1,10,25e30 The atypical clinical
manifestation of B. pertussis infection is most often incor-
rectly interpreted as post-viral bronchospasm, asthma, or
chronic sinusitis.23 Specifically, studies indicate that 12e
32% of adolescents and adults with prolonged cough, lasting
at least 1e2 weeks, are infected with B. pertussis.1,31
A number of causes were considered in order to provide
an explanation for the pertussis epidemic in various parts of
the world during the last decade. Waning immunity to B.
pertussis is regarded as the most significant cause for per-
tussis resurgence. Infection-acquired immunity and protec-
tive immunity after vaccination wane after 4e20 years and
4e12 years, respectively.17,32e34 Mutations in the genes of
pertussis toxin and pertactin are considered as an impor-
tant cause of waning vaccine induced immunity, because
vaccines may be less efficacious than in the past.5,35 More-
over, pertussis outbreaks in adolescent and adult popula-
tions, reported even in countries with high vaccination
rates,36,37 resulted in an increase in physicians’ interest
and awareness of pertussis.
As the main clinical symptom of pertussis infection in
adults is prolonged cough and not the classical severe
manifestation of whooping cough of childhood, adults tend
to seek medical advice for 2e3 weeks after the onset of
symptoms. As a result, the likelihood of culturing B. pertus-
sis is reduced and a significant number of pertussis cases in
adolescents and adults go both unrecognised and unre-
ported.38 Detection of antibodies with ELISA methods
enables detection of pertussis in adolescents and adults
who no longer harbour the pathogen,23,38,39 and also con-
tributes to the increased reporting of pertussis cases as lab-
oratory data are more likely to be reported.
Demonstration of increased antibody titers between
serum samples obtained during the acute phase of illness
Table 2 Serological studies of Bordetella pertussis in various populations
References Study population Country Method Results
Esen
et al.16
2.085 serum samples
from 2.085 healthy
subjects (6 months to
60 years old)
Turkey ELISA for IgG to PT
50e99 EU/ml and of
100 EU/ml accepted as
indicative for recent
exposure or infection
Frequencies of antibody presence at
levels of 50e99 EU/ml and of
100 EU/ml: lowest in the 0e1 years old.
Maximum frequency for 55e99 EU/ml and
100 EU/ml in 60 years old and 50e59
years old, respectivelyd
Pavlopoulou
et al.9
1001 serum samples
obtained from a
healthy population
(0 to 53 years old)
Greece ELISA for IgG to
PT> 30FDA-U/ml
In the immunized population:
Highest anti-PT levels: in the 0e2
year age group.
Lowest: in teenagers and young
adult groups.
Re-elevation of antibody titers in
the adult group of 40e50 yearsc
Polyzou
et al.8
431 serum samples
obtained from normal
healthy population
(1 daye80 years)
Greece ELISA for IgG to PT or
FHA 9 EU/ml
Prevalence of elevated IgG antibodies
35.3% in the 5e10 year group and
83.1% in the >50 years groupb
Strebel
et al.4
212 patients 10e49
years old with an
acute paroxysmal
cough or a persistent
cough illness of 7e34
days duration
USA
(Minnesota)
Culture, PCR, ELISA for IgG
or IgA to PT 2-fold
increase or IgG against PT
in a single serum specimen
3 SD above the mean of
an age-matched control
group
14.6% positive by serology (31/212
patients)
Cattaneo
et al.18
585 stored serum
samples from
normal healthy
adult population
(1e65 years old)
USA
(Tennessee)
ELISA for IgG to PT or
FHA> 2 EU/ml
First peak in PT and FHA titers in the
4e6 years age group (concurrent with
booster vaccine administration).
Second peak in the 13e17 years
age groupa
Schmitt-
Grohe
et al.49
203 adults with cough
21 days in families
of children in an
efficacy study
Germany Culture, PCR, ELISA for IgG
and IgA to PT, FHA,
pertactin, fimbriae 2,
agglutinins in single serum
sample, value 99th
percentile of controls or a
change in ELISA titer 99th
percentile fold change
limit of the assay or a 4-
fold rise in agglutinin titer
32% positive (59 by serology)
Mink
et al.10
130 UCLA students
with cough6 days
USA Culture, DFA, ELISA IgG
and IgA to PT and FHA,
agglutinins 9 single serum
titer 3 SD above mean
controls; 4-fold rise in
titer
26% positive (1 by DFA, 33 by serology)
Rosenthal
et al.27
38 adolescents and
adults (18e81 years)
with cough>6 days
USA
(Chicago)
Culture or ELISA for IgG
and IgA to PT and FHA
(2-fold rise or high single
value)
26% positive (1 by culture)
Wright
et al.41
75 adults; emergency
room visit with cough
lasting 14 days
USA
(Tennessee)
Culture or ELISA for IgG
and IgA to PT and FHA
(4-fold change or single
value 2SD above mean
of controls)
21% positive, none by culture
Nennig
et al.28
153 adults (24e78
years) with cough2
weeks
USA (San
Francisco)
ELISA on single serum
sample IgG against PT
(>2 SD above mean of
controls)
12.4% positive
(continued on next page)
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Table 2 (continued)
References Study population Country Method Results
Wirsing von
Koning
et al.26
265 adults with cough
21 days in families
of children in an
acellular vaccine
efficacy study
Germany Culture or ELISA for IgG
and IgA to PT, FHA or
pertactin (2-fold rise or
IgA value> 2 SD of mean
of controls (responses to
FHA without a response to
PT or pertactin ignored)
31% positive (1 by culture)
ELISA: Enzyme Linked Immunosorbent Assay, IgG: immunoglobulin G, IgA: immunoglobulin A, EU/ml: ELISA units/ml, PT: pertussis toxin,
FHA: Filamentous Hemagglutinin A, SD: Standard Deviation, DFA: direct fluorescent-antibody (DFA) test, FDA e U/ml: US Reference
Pertussis Antiserum (Human) Lot 3 (IgG anti-pertussis toxin) of the Food and Drug Administration (FDA), USA.
a Second peak in antibody titers in the adolescent age group interpreted as recent infection with B. pertussis.
b Prevalence of high antibody titers in subjects >50 years old interpreted as recent infection with B. pertussis.
c Re-elevation of antibody titers in the 40e50 years group was attributed to possible re-infections with B. pertussis.
d Presence of high antibody titers against B. pertussis after the age of 4e5 years is interpreted as a possible circulating infection with
B. pertussis.
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sample obtained at the convalescent phase (approximately
4e6 weeks later) has been used to diagnose pertussis
infection.4,17,40,41 Alternatively, data generated from a sig-
nificant number of studies performed on adolescents and
adult populations indicate that a single serum antibody
titer, obtained at least 3 weeks after the onset of illness,
is a valuable method to confirm pertussis diagno-
sis.4,10,13,18,42,43 Specifically, IgG antibody titers against
pertussis toxin detected with ELISA methods, that exceed
a diagnostic cutoff point, are usually used as a diagnostic
tool for pertussis in adults.4,44e47
It should be also noted that vaccines used for active
immunization against B. pertussis induce an antibody
response in non-immune persons for 4e12 years.32e34 How-
ever, as all of our patients were >18 years old it is likely
that they received their last vaccination dose against
B. pertussis in their childhood; thus, a seropositive status
of antibodies when tested indicates acute/recent infection
rather than a persistent immunity state lasting since
childhood. In addition, while one may consider that
a cross-reaction may at times ensue with serological assays
(especially against Bordetella parapertussis), serological
assays against B. pertussis toxin are considered specific
for B. pertussis infection.48
Several limitations should be taken into consideration in
the interpretation and generalization of the findings of this
study. First, only serological testing for B. pertussis was
performed in this study. There are several other tests
that may be used in the diagnosis of pertussis including
detection of B. pertussis DNA by PCR, cultures of nasopha-
ryngeal swab in BordeteGengu medium, direct fluorescent-
antibody (DFA) test, and direct detection of B. pertussis
antigens in body fluids or use of DNA probes. In particular,
rhinopharyngeal cultures in BordeteGengu medium, which
is currently regarded as the gold standard method for per-
tussis diagnosis,39,44 and PCR testing on material obtained
with rhinopharyngeal swab were not performed on any
study participant. Also, we did not have readily available
demographic and clinical data, including the effect of
recommended treatment, if any, for analysis, thus we
focused only on the analysis of serological data.In conclusion, despite the above-mentioned limitations,
our study suggests that infection due to B. pertussis should
be considered as an important possible infection in a signif-
icant proportion of adult patients presenting with a new or-
igin-cough of more than 3 weeks duration. These data add
to the relevant literature suggesting the need for booster
vaccination against B. pertussis in adolescents and adults.
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